A separate trial, SELECT, gave cardiologists a reason to pay attention
The dual-receptor mechanism of tirzepatide means it is doing things that semaglutide simply cannot do at any dose, so a true one-to-one equivalency does not exist
Clinical trials have demonstrated that semaglutide can lead to significant weight loss when used at higher doses specifically approved for obesity management
The Miller-Keystone Blood Center says that the consistency of blood donations is associated with lower risks of cancers including liver, lung, colon, and throat cancers due to the reduction in oxidative stress when iron is released from the bloodstream
The gastrointestinal profile tends to be milder with semaglutide, though individual responses vary considerably
Both semaglutide and tirzepatide belong to this class of medications, but they work in slightly different ways